Organ-on-chip and MPS

What it is

Organ-on-chip devices culture human cells in microfluidic channels with flow and, in some designs, mechanical forces. Microphysiological systems (MPS) is the broader term and includes multi-organ circuits and organoid-on-chip formats.

Where it is used

Pharma uses MPS mostly for investigative toxicology, ADME and disease biology. Liver, gut, kidney and CNS or blood-brain barrier models lead demand. Results usually inform internal go or no-go decisions rather than replace required animal studies.

Evidence base

• Emulate's blinded study of 27 drugs reported 87% sensitivity and 100% specificity for drug-induced liver injury. The study is company-authored.
• FDA scientists showed that assay choices can distort chip readouts.
• Throughput is rising: Emulate's AVA system runs up to 96 chips per run, and Vivodyne and Xellar pair human tissues with robotics and AI.

Commercial picture

Tracxn counts 46 organ-on-chip companies with about $478M of equity raised. Strategic buyers are moving in: Bruker took a majority stake in MIMETAS (August 2026) and Quris-AI bought Nortis (October 2024). Private revenue is mostly undisclosed. One public data point, the Hesperos S-1, showed about $5M of annual revenue in 2022.

Players tracked

Emulate, CN Bio, MIMETAS, TissUse, Hesperos, AxoSim, Vivodyne, Xellar Biosystems, Quris-AI, NETRI, Cellbox Labs. See the Companies page for the full list.

Open questions

• Can chip unit economics work at pharma screening scale?
• Will the first ISTAND qualification create a required purchase or only a reference?
• Will the data, rather than the hardware, become the main product?